Business Description
Glaukos Corp
NAICS : 339112
SIC : 3845
ISIN : US3773221029
Description
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.08 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.14 | |||||
| Debt-to-EBITDA | -1.08 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 18.93 | |||||
| Beneish M-Score | -2.1 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 4.7 | |||||
| 3-Year EBITDA Growth Rate | -284.1 | |||||
| 3-Year EPS without NRI Growth Rate | -30.9 | |||||
| 3-Year FCF Growth Rate | -37.1 | |||||
| 3-Year Book Growth Rate | 2.8 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 27.11 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 20.73 | |||||
| 9-Day RSI | 24.85 | |||||
| 14-Day RSI | 28.63 | |||||
| 3-1 Month Momentum % | 13.64 | |||||
| 6-1 Month Momentum % | 27.12 | |||||
| 12-1 Month Momentum % | 79.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.99 | |||||
| Quick Ratio | 5.22 | |||||
| Cash Ratio | 4.25 | |||||
| Days Inventory | 206.69 | |||||
| Days Sales Outstanding | 48.5 | |||||
| Days Payable | 48.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.3 | |||||
| Shareholder Yield % | 2.7 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.48 | |||||
| Operating Margin % | -28.2 | |||||
| Net Margin % | -38.17 | |||||
| FCF Margin % | -17.5 | |||||
| ROE % | -24.29 | |||||
| ROA % | -15.59 | |||||
| ROIC % | -18.01 | |||||
| 3-Year ROIIC % | -412.9 | |||||
| ROC (Joel Greenblatt) % | -61.9 | |||||
| ROCE % | -15.65 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 16.52 | |||||
| PB Ratio | 8.83 | |||||
| Price-to-Tangible-Book | 15.49 | |||||
| EV-to-EBIT | -48.49 | |||||
| EV-to-Forward-EBIT | -123.52 | |||||
| EV-to-EBITDA | -68.73 | |||||
| EV-to-Forward-EBITDA | -160.72 | |||||
| EV-to-Revenue | 17.14 | |||||
| EV-to-Forward-Revenue | 13.6 | |||||
| EV-to-FCF | -97.22 | |||||
| Price-to-GF-Value | 1.44 | |||||
| Price-to-Projected-FCF | 30.56 | |||||
| Price-to-Median-PS-Value | 1.61 | |||||
| Price-to-Net-Current-Asset-Value | 28.01 | |||||
| Price-to-Net-Cash | 60.96 | |||||
| Earnings Yield (Greenblatt) % | -2.06 | |||||
| FCF Yield % | -1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Glaukos Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 355.52 | ||
| EPS (TTM) (€) | -2.607 | ||
| Beta | 0.22 | ||
| 3-Year Sharpe Ratio | 1.12 | ||
| 3-Year Sortino Ratio | 2.1 | ||
| Volatility % | 34.92 | ||
| 14-Day RSI | 28.63 | ||
| 14-Day ATR (€) | 4.253283 | ||
| 20-Day SMA (€) | 138.35 | ||
| 12-1 Month Momentum % | 79.64 | ||
| 52-Week Range (€) | 76.5 - 152 | ||
| Shares Outstanding (Mil) | 56.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Glaukos Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Glaukos Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Glaukos Corp Frequently Asked Questions
What is Glaukos Corp(FRA:6GJ)'s stock price today?
The current price of FRA:6GJ is €114.00. The 52 week high of FRA:6GJ is €152.00 and 52 week low is €76.50.
When is next earnings date of Glaukos Corp(FRA:6GJ)?
The next earnings date of Glaukos Corp(FRA:6GJ) is 2025-05-01 Est..
Does Glaukos Corp(FRA:6GJ) pay dividends? If so, how much?
Glaukos Corp(FRA:6GJ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers